{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:26:37Z","timestamp":1790745997188,"version":"4.1.0"},"reference-count":96,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:p>This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and\/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant.<\/jats:p>","DOI":"10.1590\/s0004-27302006000200024","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T11:18:35Z","timestamp":1155122315000},"page":"377-389","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacological treatment of obesity"],"prefix":"10.1590","volume":"50","author":[{"given":"Marcio C.","family":"Mancini","sequence":"first","affiliation":[{"name":"University of S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Halpern","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Preventing and managing the global epidemic","year":"1998"},{"key":"ref2","series-title":"From theory to practice: Obesity in Europe - 88","first-page":"311","volume-title":"Long-term pharmacoterapy in the management of obesity","author":"Guy-Grand B","year":"1989"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJM199309303291406","article-title":"Social and economic consequences of overweight in adolescence and young adulthood","volume":"329","author":"Gortmaker SL","year":"1993","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(98)22029-0","article-title":"Obesity: a time bomb to be refused","volume":"352","author":"Bray GA","year":"1998","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/bmj.311.7002.437","article-title":"Obesity in Britain: gluttony or sloth?","volume":"311","author":"Prentice AM","year":"1995","journal-title":"Br Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1447","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1467-789X.2003.00083.x","article-title":"Treatment of obesity: an update on anti-obesity medications","volume":"4","author":"Halpern A","year":"2003","journal-title":"Obes Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1111\/j.1753-4887.1996.tb03904.x","article-title":"Dietary intake and physical activity as \"predictors\" of weight gain in observational, prospective studies","volume":"54","author":"Williamson DF","year":"1996","journal-title":"Nutr Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0029-6643","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0773.1993.tb01537.x","article-title":"Neurochemical mechanism of action of anorectic drugs","volume":"73","author":"Samanin R","year":"1993","journal-title":"Pharmacol Toxicol","ISSN":"https:\/\/id.crossref.org\/issn\/0901-9928","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/j.1550-8528.1995.tb00213.x","article-title":"Biological actions of drugs affecting serotonin and eating","volume":"3","author":"Garattini S","year":"1995","journal-title":"Obes Res","ISSN":"https:\/\/id.crossref.org\/issn\/1071-7323","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF02245152","article-title":"A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine","volume":"107","author":"Heal DJ","year":"1992","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.7123250","article-title":"(+)-Amphetamine binding to rat hypothalamus: relation to anorexic potency of phenethylamines","volume":"218","author":"Paul SM","year":"1982","journal-title":"Science","ISSN":"https:\/\/id.crossref.org\/issn\/0036-8075","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1073\/pnas.82.18.6320","article-title":"Glucostatic regulation of (+)-[3H]amphetamine binding in the hypothalamus: correlation with Na+\/K+-ATPase activity","volume":"82","author":"Angel I","year":"1985","journal-title":"Proc Natl Acad Sci USA","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1001\/jama.1947.02880340022005","article-title":"The mechanism of amphetamine-induced loss of weight","volume":"134","author":"Harris SC","year":"1947","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref14","first-page":"139","article-title":"Metabolic effects of fenfluramine: a double-blind study","volume":"51","author":"Petrie JC","year":"1975","journal-title":"Postgrad Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0032-5473","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1749-6632.1989.tb53272.x","article-title":"Serotoninergic drug potentates the satiating capacity of food: action of [scap]d-fenfluramine in obese subjects","volume":"575","author":"Blundell JE","year":"1989","journal-title":"Ann NY Acad Sci"},{"key":"ref16","first-page":"R802","article-title":"Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate","volume":"277","author":"Smith BK","year":"1999","journal-title":"Am J Physiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9513","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0031-9384(95)00149-D","article-title":"Effect of amphetamine on human macronutrient intake","volume":"58","author":"Foltin RW","year":"1995","journal-title":"Physiol Behav","ISSN":"https:\/\/id.crossref.org\/issn\/0031-9384","issn-type":"print"},{"key":"ref18","first-page":"S25","article-title":"Sibutramine: a review of the pharmacology of a novel anti-obesity agent","volume":"21","author":"Stock MJ","year":"1997","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref19","first-page":"684","article-title":"The pharmacokinetics of dexfenfluramine in obese and non-obese subjects","volume":"39","author":"Cheymol G","year":"1995","journal-title":"Br J Clin Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0306-5251","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01060039","article-title":"The oral bioavailability and pharmacokinetics of soluble and resin-bound forms of amphetamine and phentermine in man","volume":"1","author":"Hinsvark ON","year":"1973","journal-title":"J Pharmacokinet Biopharm","ISSN":"https:\/\/id.crossref.org\/issn\/0090-466X","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1139\/y86-122","article-title":"Metabolism and disposition of N-(2-cyanoethyl) amphetamine (fenproporex) and amphetamine: study in the rat brain","volume":"64","author":"Coutts RT","year":"1986","journal-title":"Can J Physiol Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0008-4212","issn-type":"print"},{"key":"ref22","first-page":"1025","article-title":"A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats","volume":"29","author":"Mattei R","year":"1996","journal-title":"Braz J Med Biol Res","ISSN":"https:\/\/id.crossref.org\/issn\/0100-879X","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1081\/DMR-100100562","article-title":"Illegal or legitimate use?: Precursor compounds to amphetamine and methamphetamine","volume":"32","author":"Musshoff E","year":"2000","journal-title":"Drug Metab Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0360-2532","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-199200710-00005","article-title":"Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers","volume":"7","author":"Silverstone PH","year":"1992","journal-title":"Int Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0268-1315","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003495-199000393-00006","article-title":"Carbohydrate craving: Relationship between carbohydrate intake and disorders of mood","volume":"39","author":"Wurtman JJ","year":"1990","journal-title":"Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF02801976","article-title":"A comparison of the effects of d- and l-fenfluramine and d-amphetamine on energy and macronutrient intake in human subjects","volume":"106","author":"Goodall EM","year":"1992","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref27","first-page":"25","article-title":"Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects: A double-blind placebo-controlled study","volume":"17","author":"Lafreniere F","year":"1993","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF02244895","article-title":"Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers","volume":"112","author":"Goodall EM","year":"1993","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.470100504","article-title":"Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women","volume":"10","author":"Cowen PJ","year":"1995","journal-title":"Hum Psychopharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002130050178","article-title":"Sumatriptan decreases food intake and increases plasma growth hormone in healthy women","volume":"129","author":"Boeles S","year":"1997","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJM198104163041602","article-title":"The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients","volume":"304","author":"Tuck ML","year":"1981","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray GA","year":"1999","journal-title":"Obes Res","ISSN":"https:\/\/id.crossref.org\/issn\/1071-7323","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-134-1-200101020-00007","article-title":"the Trials of Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II","volume":"134","author":"Stevens VJ","year":"2001","journal-title":"Ann Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-4819","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0033-0620(99)70008-3","article-title":"Obesity and hypertension","volume":"42","author":"Mikhail N","year":"1999","journal-title":"Prog Cardiovasc Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0033-0620","issn-type":"print"},{"key":"ref35","first-page":"612","article-title":"A six-month study of the effects of dexfenfluramine on partially successful dieters","volume":"47","author":"Noble RE","year":"1990","journal-title":"Curr Ther Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/BF00265922","article-title":"Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients","volume":"42","author":"Kolanowski J","year":"1992","journal-title":"Eur J Clin Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0031-6970","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajcn\/67.4.611","article-title":"Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women","volume":"67","author":"Fletchner Mors M","year":"1998","journal-title":"Am J Clin Nutr","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9165","issn-type":"print"},{"key":"ref38","first-page":"397","article-title":"Beneficial health effects of modest weight-loss","volume":"16","author":"Goldstein DJ","year":"1992","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/j.1550-8528.1999.tb00436.x","article-title":"Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study","volume":"7","author":"Sj\u00f6str\u00f6m CD","year":"1999","journal-title":"Obes Res","ISSN":"https:\/\/id.crossref.org\/issn\/1071-7323","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/diab.22.11.858","article-title":"Hypoglycemic action of fenfluramine in diabetes mellitus","volume":"22","author":"Turtle JR","year":"1973","journal-title":"Diabetes","ISSN":"https:\/\/id.crossref.org\/issn\/0012-1797","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/acta.0.1280251","article-title":"Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients","volume":"128","author":"Andersen PH","year":"1993","journal-title":"Acta Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0001-5598","issn-type":"print"},{"key":"ref42","first-page":"274","article-title":"Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM","volume":"21","author":"Marks SJ","year":"1997","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-199300810-00008","article-title":"The prolactin response to d- and l-fenfluramine and to d-amphetamine in human subjects","volume":"8","author":"Feeney S","year":"1993","journal-title":"Int Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0268-1315","issn-type":"print"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0006-3223(93)90008-2","article-title":"Prolactin response to fenfluramine and placebo challenge following maintenance pharmacoterapy withdrawal in remitted depressed patients","volume":"33","author":"Shapira B","year":"1993","journal-title":"Biol Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2265.1997.1620975.x","article-title":"Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine","volume":"46","author":"Boushaki FZ","year":"1997","journal-title":"Clin Endocrinol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0026-0495(94)90176-7","article-title":"The effect of hypocaloric diet with and without d-fenfluramine treatment on growth hormone release after growth hormone-releasing factor stimulation in patients with android obesity","volume":"43","author":"Medeiros-Neto G","year":"1994","journal-title":"Metabolism","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2265.1996.727548.x","article-title":"Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women","volume":"44","author":"Kars ME","year":"1996","journal-title":"Clin Endocrinol"},{"key":"ref48","first-page":"20","article-title":"Extra-anorectic actions of mazindol","volume":"25","author":"Jonderko K","year":"1989","journal-title":"Isr J Med Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0021-2180","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study","volume":"2","author":"Finer N","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"ref50","first-page":"175","article-title":"Sibutramine\/Diabetes Clinical Study Group","volume":"2","author":"Fujioka K","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"ref51","first-page":"169","article-title":"Modulation of the thermic effect of food by fenfluramine","volume":"10","author":"Levitsky DA","year":"1986","journal-title":"Int J Obes","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref52","first-page":"91","article-title":"The acute effect of fexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study","volume":"17","author":"Scalfi L","year":"1993","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0026-0495(95)90209-0","article-title":"Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction","volume":"44","author":"Van Gaal LF","year":"1995","journal-title":"Metabolism","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"ref54","first-page":"613","article-title":"The effect of long-term dexfenfluramine treatment on 24-hour energy-expenditure in man: a double-blind placebo controlled study","volume":"14","author":"Breum L","year":"1990","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/j.1550-8528.1998.tb00324.x","article-title":"Effects of sibutramine on resting metabolic rate and weight loss in overweight women","volume":"6","author":"Seagle HM","year":"1998","journal-title":"Obes Res","ISSN":"https:\/\/id.crossref.org\/issn\/1071-7323","issn-type":"print"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ajcn\/68.6.1180","article-title":"Thermogenic effects of sibutramine in humans","volume":"68","author":"Hansen DL","year":"1998","journal-title":"Am J Clin Nutr","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9165","issn-type":"print"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ajcn\/57.2.120","article-title":"Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women","volume":"57","author":"Alger S","year":"1993","journal-title":"Am J Clin Nutr","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9165","issn-type":"print"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1590\/S0004-27302000000100015","article-title":"Efic\u00e1cia e tolerabilidade das subst\u00e2ncias calorig\u00eanicas: ioimbina, triiodotironina, aminofilina combinada a efedrina e fenilpropanolamina no tratamento da obesidade a curto prazo","volume":"44","author":"Rascovski A","year":"2000","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref59","first-page":"678","article-title":"Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans","volume":"19","author":"Liu YL","year":"1995","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref60","first-page":"163","article-title":"Does ephedrine promote weight loss in low-energy adapted obese women?","volume":"11","author":"Pasquali R","year":"1987","journal-title":"Int J Obes","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref61","first-page":"224","article-title":"Tratamento farmacol\u00f3gico da obesidade: Drogas termog\u00eanicas","volume":"40","author":"Halpern A","year":"1996","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/0026-0495(92)90015-3","article-title":"Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxantines: adenosine antagonism or phosphodiesterase inhibition","volume":"41","author":"Dulloo AG","year":"1992","journal-title":"Metabolism","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0026-0495(91)90117-F","article-title":"Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study","volume":"40","author":"Astrup A","year":"1991","journal-title":"Metabolism","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"ref64","first-page":"141","article-title":"Ephedrine, caffeine and aminophilline preparation: na alternative in the treatment of obesity","volume":"14","author":"Mancini MC","year":"1990","journal-title":"Int J Obes","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly HM","year":"1997","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199708283370911","article-title":"Further cases of valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Graham DJ","year":"1997","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref67","first-page":"S227","article-title":"Echocardiographic evaluation of 70 patients using dexfenfluramine (abstracted)","volume":"22","author":"Leite CC","year":"1998","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo","volume":"339","author":"Weissman NJ","year":"1998","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-supressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim L","year":"1996","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1253\/jcj.64.218","article-title":"Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report","volume":"64","author":"Hagiwara M","year":"2000","journal-title":"Jpn Circ"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/hrt.74.6.660","article-title":"Appetite supressants and primary pulmonary hypertension in the United Kingdom","volume":"74","author":"Thomas SH","year":"1995","journal-title":"Br Heart J","ISSN":"https:\/\/id.crossref.org\/issn\/0007-0769","issn-type":"print"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004850-199300810-00012","article-title":"Psychosis following readministration of diethylpropion: a possible role for kinding?","volume":"8","author":"Little JD","year":"1993","journal-title":"Int Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0268-1315","issn-type":"print"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1345\/aph.18319","article-title":"Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity","volume":"33","author":"Luque CA","year":"1999","journal-title":"Ann Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/1060-0280","issn-type":"print"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled multicenter trial","volume":"160","author":"McMahon FG","year":"2000","journal-title":"Arch Int Med"},{"key":"ref75","series-title":"Phenylpropanolamine and risk of hemorrhagic stroke: final report of the hemorrhagic stroke project","author":"Horwitz RI"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"185S","DOI":"10.1093\/ajcn\/55.1.185s","article-title":"Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice","volume":"55","author":"Neilsen JA","year":"1992","journal-title":"Am J Clin Nutr","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9165","issn-type":"print"},{"key":"ref77","first-page":"361","article-title":"The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects","volume":"14","author":"McGuirk J","year":"1990","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref78","first-page":"S67","article-title":"A randomized double-blind clinical trial of fluoxetine in obese diabetics","volume":"16","author":"Gray DS","year":"1992","journal-title":"Int J Obes Relat Metab Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1550-8528.1995.tb00189.x","article-title":"Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial","volume":"3","author":"Wadden TA","year":"1995","journal-title":"Obes Res","ISSN":"https:\/\/id.crossref.org\/issn\/1071-7323","issn-type":"print"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF03347875","article-title":"Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients","volume":"19","author":"Ricca V","year":"1996","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/bmj.322.7299.1406","article-title":"Extracts from \"clinical evidence\": Obesity","volume":"322","author":"Arterburn D","year":"2001","journal-title":"Br Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1447","issn-type":"print"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/j.1552-4604.1995.tb04034.x","article-title":"Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers","volume":"35","author":"Zhi J","year":"1995","journal-title":"J Clin Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0091-2700","issn-type":"print"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0002-8223(98)00706-8","article-title":"Modern medical management of obesity: the role for pharmacological intervention","volume":"98","author":"Aronne LJ","year":"1998","journal-title":"J Am Diet Assoc","ISSN":"https:\/\/id.crossref.org\/issn\/0002-8223","issn-type":"print"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat","volume":"281","author":"Davidson MH","year":"1999","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","article-title":"Treatment with orlistat reduces cardiovascular risk in obese patients","volume":"16","author":"Zavoral JH","year":"1998","journal-title":"J Hypertens","ISSN":"https:\/\/id.crossref.org\/issn\/0263-6352","issn-type":"print"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sj\u00f6strom L","year":"1998","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes","volume":"21","author":"Hollander PA","year":"1998","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1463-1326.2003.00262.x","article-title":"Latin-american trial of orlistat for weight loss and improvement in glycemic profile in obese diabetic patients","volume":"5","author":"Halpern A","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"ref89","first-page":"241","article-title":"Lipase inhibition: a novel concept in the treatment of obesity","volume":"17","author":"Drent ML","year":"1993","journal-title":"Int J Obes","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref90","first-page":"221","article-title":"Orlistat, a lipase inhibitor, in the treatment of human obesity: a multiple dose study","volume":"19","author":"Drent ML","year":"1995","journal-title":"Int J Obes","ISSN":"https:\/\/id.crossref.org\/issn\/0307-0565","issn-type":"print"},{"key":"ref91","first-page":"125","article-title":"Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month-dose-ranging study","volume":"54","author":"Van Gaal LF","year":"1998","journal-title":"Eur J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0014-2999","issn-type":"print"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00128072-200103060-00001","article-title":"Pharmacological treatment of obesity in paediatric patients","volume":"3","author":"Daniels S","year":"2001","journal-title":"Paediatr Drugs"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00024677-200504020-00001","article-title":"Diabesity: are weight loss medications effective?","volume":"4","author":"Halpern A","year":"2005","journal-title":"Treat Endocrinol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson JS","year":"2004","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2337\/diacare.27.3.856-c","volume":"27","year":"2004","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"van Gaal L","year":"2005","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v50n2\/29321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T15:49:37Z","timestamp":1555775377000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302006000200024&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0004-27302006000200024"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302006000200024","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}